About: http://data.cimple.eu/news-article/3fef2b4e1963242ab9fe2dfe860c268558003081289900c38bf4b75c

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/3fef2b4e1963242ab9fe2dfe860c268558003081289900c38bf4b75c Goto Sponge NotDistinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	The University of Oxford said Monday it has launched a trial in which people who have already had Covid-19 are deliberately reinfected. The carefully controlled study will look at the kind of immune response mounted by the volunteers. The scientists will know "exactly when the second infection occurs, and exactly how much virus they got," Helen McShane, a professor of vaccinology, said in a statement. She said the trial "may help us to design tests that can accurately predict whether people are protected" after a prior infection. Anyone who suffers symptoms will receive the Regeneron antibody treatment used to treat Covid-19 patients. The University of Oxford's "first-of-a-kind" tests are funded by the Wellcome Trust. At the start of the trial, up to 64 fit and healthy volunteers aged 18 to 30 will be deliberately reinfected with the original Wuhan strain. They will be quarantined for at least 17 days in a special hospital suite, having lung and heart scans. They will then have follow-up appointments and be monitored for a year. "This study has the potential to transform our understanding by providing high-quality data," said Shobana Balasingam, vaccines senior research advisor at Wellcome. The trial's initial phase will look at the minimum dose that allows the virus to start replicating without symptoms in some 50 percent of volunteers. Then in the second phase, another group of volunteers will all receive this established minimum dose. The trial comes as a London hospital has isolated a group of healthy volunteers while exposing them to the virus, in a world first. That began in March and is being carried out in collaboration between Imperial College London and the company hVIVO at the Royal London Hospital. Those who have been infected in a controlled way are monitored to see how their illness progresses and how drugs and vaccines could work against it. am/phz/bp
schema:headline	UK trial reinfects volunteers who have had coronavirus
schema:mentions	The B-Sides The Scientists Imperial College London Respiratory disease Hertz Antibody University of Oxford Immune system Wuhan Virus United Kingdom Vaccine Coronavirus Coronavirus disease 2019 Helen McShane Shobana Wellcome Trust Royal London Hospital
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2021-04-19 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	positive sentiment
http://data.cimple...readability_score	75 (xsd:integer)
http://data.cimple...tology#hasEmotion	happiness

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 5 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software